Expanding the clinical indications for α₁-antitrypsin therapy

Keyphrases

• Liver 100%
• Clinical Indications 100%
• Antitrypsin 100%
• Graft-versus-host Disease (GvHD) 100%
• Cystic Fibrosis 100%
• Circulating Levels 100%
• Multiple Sclerosis 50%
• Lung 50%
• Inflammatory Bowel Disease 50%
• Clinical Trials 50%
• Disease Progression 50%
• Interleukin-10 50%
• Cell Differentiation 50%
• Replacement Therapy 50%
• Cell Death 50%
• Interleukin-1β 50%
• Type 1 Diabetes Mellitus (T1DM) 50%
• Type 2 Diabetes Mellitus (T2DM) 50%
• Human Plasma 50%
• Serine Protease Inhibitor 50%
• Caspase-1 50%
• Interleukin-1 Receptor Antagonist (IL-1Ra) 50%
• Elastase 50%
• Regulatory T (Treg) Cells 50%
• Plasma-derived 50%
• Protective Effect 50%
• Dendritic Cell Maturation 50%
• Type I Diabetes 50%
• Acute Myocardial Infarction 50%
• Emphysema 50%
• Acute Phase Response 50%
• T Lymphocyte Response 50%
• Potential Treatments 50%
• Viral Infection 50%
• Immune-mediated Diseases 50%
• Inherited mutation 50%
• Rheumatoid Arthritis 50%
• Influenza 50%
• AIDS/HIV 50%
• Serine Protease 50%
• Safe Treatment 50%
• Transplant Rejection 50%
• Proteasome Inhibition 50%
• Proteinase 3 50%

Medicine and Dentistry

• Disease 100%
• Trypsin Inhibitor 100%
• Cystic Fibrosis 100%
• Graft Versus Host Reaction 100%
• Clinical Trial 50%
• Disease Exacerbation 50%
• Human Immunodeficiency Virus 50%
• T Lymphocyte 50%
• Maturity Onset Diabetes of the Young 50%
• Inflammatory Bowel Disease 50%
• Infusion 50%
• Clinical Study 50%
• Serine Proteinase Inhibitor 50%
• Interleukin 1beta Converting Enzyme 50%
• Elastase 50%
• Regulatory T Cell 50%
• Graft Rejection 50%
• Insulin Dependent Diabetes Mellitus 50%
• Interleukin 1 50%
• Dendritic Cell 50%
• Cell Death 50%
• Interleukin 10 50%
• Acute Phase Response 50%
• Antiinfective Agent 50%
• Cell Differentiation 50%
• Rheumatoid Arthritis 50%
• Immunosuppressant 50%
• Acute Heart Infarction 50%
• Myeloblastin 50%
• Virus Infection 50%
• Emphysema 50%
• Serine Proteinase 50%
• Interleukin 1 Receptor Blocking Agent 50%
• Substitution Therapy 50%
• Proteinase Inhibition 50%
• Multiple Sclerosis 50%
• Cell Maturation 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Graft Versus Host Reaction 100%
• Cystic Fibrosis 100%
• Trypsin Inhibitor 100%
• Clinical Study 50%
• HIV 50%
• Proteinase 50%
• Antiinfective Agent 50%
• Replacement Therapy 50%
• Inflammatory Bowel Disease 50%
• Clinical Trial 50%
• Non Insulin Dependent Diabetes Mellitus 50%
• Preclinical Study 50%
• Interleukin 1 50%
• Interleukin 1beta Converting Enzyme 50%
• Interleukin 1 Receptor Blocking Agent 50%
• Serine Proteinase Inhibitor 50%
• Multiple Sclerosis 50%
• Acute Heart Infarction 50%
• Serine Proteinase 50%
• Elastase 50%
• Virus Infection 50%
• Myeloblastin 50%
• Emphysema 50%
• Insulin Dependent Diabetes Mellitus 50%
• Graft Rejection 50%
• Interleukin 10 50%
• Rheumatoid Arthritis 50%
• Immunosuppressive Agent 50%
• Disease Exacerbation 50%